1 Min Read
Feb 12 (Reuters) - Azurrx Biopharma Inc:
* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.